- LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments
- Its lead compound, LB-100, targets PP2A and is advancing through multiple clinical trials with a favorable safety profile
- The company is building a differentiated oncology pipeline supported by experienced leadership and scientific expertise
LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target.
LIXTE’s platform is built on its proprietary LB-100 compound, a one-of-a-kind inhibitor of Protein Phosphatase 2A (“PP2A”). PP2A is a critical enzyme involved in various cellular processes, including cell growth regulation, DNA repair, and modulation of the immune response. Through the selective inhibition of PP2A, LB-100 is strategically designed to make cancer cells more treatable while also boosting the body’s immunity to tumors.
This strategic approach is important because resistance and limited efficacy are major impediments in oncology. Different cancers fail to respond adequately to immunotherapy. The company’s strategy is not aimed at replacing these therapies, but rather at improving them, making it possible for standard treatments to work for more patients. Clinical and preclinical research has shown that LB-100 can alter cancer cell DNA repair mechanisms, promoting cytokine production and increasing neoantigen formation, while also boosting T-cell proliferation, which potentially improves treatment outcomes when combined with existing therapies.
LB-100 has shown positive signs in its Phase 1 clinical trials and has been the subject of over 25 scientific publications documenting its anti-cancer activity across different cancer models. The compound leverages cost-effective manufacturing, convenient intravenous delivery, and Good Manufacturing Practice (“GMP”) production, helping its scalability as clinical development progresses.
The company is also working on a growing clinical pipeline aimed at solid tumors with high unmet medical needs. Planned and ongoing research includes LB-100 in combination with chemotherapy for advanced tissue sarcoma, in addition to immunotherapy for metastatic microsatellite-stable (“MSS”) and ovarian clear cell carcinoma.
Extending beyond pharmacology, LIXTE’s subsidiary Liora Technologies is advancing next-generation radiation delivery infrastructure to address another critical bottleneck in oncology care. While LB-100 is designed to improve how tumors respond to immunotherapy and chemotherapy, Liora’s technology focuses on enhancing the precision, accessibility, and cost-efficiency of radiation therapy itself, positioning LIXTE as a company improving cancer treatment effectiveness across multiple dimensions.
LiGHT is a first-of-its-kind, electronically controlled proton therapy platform built to meaningfully improve how radiation is delivered to tumors. Unlike traditional proton systems that depend on bulky gantries and mechanical energy degraders, LiGHT uses a compact linear accelerator (“LINAC”) that adjusts beam energy electronically and in real time – up to 200 times per second. This approach allows clinicians to deliver radiation with greater precision while reducing unnecessary exposure to surrounding healthy tissue.
These indications represent areas where current treatment options are limited, and outcomes remain poor, highlighting the potential impact of LIXTE’s enhancer-based approach. The company is currently led by a management team with expertise in clinical operations, drug development, and capital markets, in addition to a Scientific Advisory Committee that includes globally renowned leaders in molecular medicine and oncology. The blend of operational experience and scientific leadership positions the company to leverage opportunities in the ecosystem.
With the rapid shift of oncology toward the combination of precision-based approaches and combination therapies, LIXTE Biotech’s focus on highlighting the power of already existing cancer treatments sets it apart. With a one-of-a-kind mechanism, proof-of-concept data, and a rapidly expanding clinical pipeline, the company is leading the change in how cancer therapies can become more effective, especially for patients faced with difficult diagnoses.
For more information, visit the company website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
